We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
-$476M
Cap. Flow %
-10.67%
Top 10 Hldgs %
48.58%
Holding
171
New
10
Increased
26
Reduced
81
Closed
23

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$53M
2
BEAM icon
Beam Therapeutics
BEAM
+$23M
3
SYK icon
Stryker
SYK
+$17.7M
4
ABBV icon
AbbVie
ABBV
+$17.5M
5
BAX icon
Baxter International
BAX
+$14.9M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$204M
2
ARVN icon
Arvinas
ARVN
+$45.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$34.7M
4
VRNA
Verona Pharma
VRNA
+$30.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Technology 0.01%
3 Communication Services 0.01%
4 Consumer Discretionary 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHR icon
76
Phreesia
PHR
$662M
$9.61M 0.22%
376,163
-29,530
-7% -$803K
SRPT icon
77
Sarepta Therapeutics
SRPT
$1.82B
$9.52M 0.21%
149,113
-22,204
-13% -$2.34M
HUM icon
78
Humana
HUM
$48B
$7.49M 0.17%
28,298
-69
-0.2% -$18.7K
LH icon
79
Labcorp
LH
$23.2B
$6.55M 0.15%
28,141
+27,925
+12,928% +$6.78M
GILD icon
80
Gilead Sciences
GILD
$167B
$6.17M 0.14%
55,022
+6,593
+14% +$680K
CSTL icon
81
Castle Biosciences
CSTL
$733M
$6.03M 0.14%
301,103
-444,879
-60% -$11M
EVH icon
82
Evolent Health
EVH
$654M
$5.82M 0.13%
614,337
-499,321
-45% -$5.04M
GKOS icon
83
Glaukos
GKOS
$9.21B
$5.5M 0.12%
55,926
-4,949
-8% -$660K
WAY
84
Waystar Holding Corp
WAY
$4.27B
$5.4M 0.12%
144,426
-13,472
-9% -$533K
ALT icon
85
Altimmune
ALT
$558M
$5.28M 0.12%
1,056,793
+111,347
+12% +$705K
CNC icon
86
Centene
CNC
$32.8B
$5.23M 0.12%
86,218
-238
-0.3% -$14.4K
BIO icon
87
Bio-Rad Laboratories Class A
BIO
$8.15B
$5.23M 0.12%
21,476
-12,075
-36% -$3.63M
ASTH icon
88
Astrana Health
ASTH
$2.23B
$5.06M 0.11%
163,155
-42,084
-21% -$1.4M
BTSG icon
89
BrightSpring Health Services
BTSG
$13.9B
$4.37M 0.1%
241,749
+67,597
+39% +$1.33M
BDTX icon
90
Black Diamond Therapeutics
BDTX
$103M
$4.24M 0.09%
2,733,547
-5,784,292
-68% -$12.1M
VRNA
91
DELISTED
Verona Pharma
VRNA
$3.89M 0.09%
61,261
-507,694
-89% -$30.4M
GPCR icon
92
Structure Therapeutics
GPCR
$3.45B
$3.84M 0.09%
221,715
-263,335
-54% -$6.45M
KMTS
93
Kestra Medical Technologies
KMTS
$1.43B
$3.33M 0.07%
+133,761
New +$3.07M
SPY icon
94
State Street SPDR S&P 500 ETF Trust
SPY
$782B
$3.17M 0.07%
5,660
– –
LEGN icon
95
Legend Biotech
LEGN
$4.31B
$3.09M 0.07%
91,191
-76,150
-46% -$2.73M
PFE icon
96
Pfizer
PFE
$143B
$3.06M 0.07%
120,746
-20,814
-15% -$545K
AZN icon
97
AstraZeneca
AZN
$262B
$2.94M 0.07%
20,000
+2,150
+12% +$311K
CAH icon
98
Cardinal Health
CAH
$53.5B
$2.86M 0.06%
20,776
-1,522
-7% -$194K
ILMN icon
99
Illumina
ILMN
$28.2B
$2.19M 0.05%
27,624
-16,079
-37% -$1.74M
CVS icon
100
CVS Health
CVS
$137B
$2.15M 0.05%
31,755
+9,911
+45% +$593K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2025 Portfolio in Review

As of Q1 2025, Bellevue Group held 171 positions worth $4.46B, down 14% from $5.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $476M in Q1 2025, closing 23 positions and reducing 81 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $204M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Bellevue Group opened a new position in Akero Therapeutics worth $50.6M.

  • Bellevue Group's largest Q1 2025 buy was Akero Therapeutics: 1,250,666 shares worth $50.6M.
  • Bellevue Group added most to Beam Therapeutics in Q1 2025, an estimated $23M increase.
  • Bellevue Group's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $34.7M.
  • Bellevue Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $204M.
  • Bellevue Group's ten largest holdings make up 49% of its $4.46B portfolio in Q1 2025.
  • Bellevue Group opened 10 new positions and closed 23 in Q1 2025.
  • Bellevue Group's portfolio value fell 14% quarter-over-quarter to $4.46B.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.